Navigation Links
China's Environment, Health Examined in New Wilson Center Report
Date:2/7/2008

China Environment Series Authors See Solutions in Regulation, Research, NGOs, and International Assistance

WASHINGTON, Feb. 7 /PRNewswire-USNewswire/ -- 2007 was a significant year for China's environment. An estimated 750,000 people in China died from respiratory illnesses related to air pollution, while approximately 60,000 died from waterborne diseases. China's food processing and production sectors made headlines around the globe. Growing desertification in north and northwest China due to excessive water use and land mismanagement created more intense sand storms that affected the economy and health in China and Northeast Asia. In addition, China most likely surpassed the United States as the leading emitter of greenhouse gasses -- and while the central government set laudable energy efficiency goals, it recently admitted that China had not met them.

The latest edition of the China Environment Series (CES), the flagship publication of the China Environment Forum (CEF) (http://www.wilsoncenter.org/cef) at the Woodrow Wilson International Center for Scholars, examines these and other increasingly serious environmental problems in China, focusing on linkages between health and the environment and identifying promising trends and opportunities for U.S. collaboration with China.

Link to CES 9: http://www.wilsoncenter.org/index.cfm?topic_id=1421&fuseaction=topics.publi cations&group_id=375132

ENVIRONMENTAL HEALTH

-- Xiaoqing Lu and Bates Gill see incredible challenges facing China as it attempts to address its environmental health problems, but they identify important next steps for policymakers, NGOs, and researchers.

-- CEF's Jennifer L. Turner and Linden Ellis turn attention to China's domestic food safety problems, which stem from unsustainab
'/>"/>

SOURCE Woodrow Wilson International Center for Scholars
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Environment, Energy and Ethics conference at UD, Sept. 21-23
2. Free Childrens Dental Day; Expert Source on Childrens Dental Health Available
3. Be Healthy Be Happy(TM) with the Motherhood(R) Maternity and March of Dimes(R) Bracelet
4. Accipiter Capital Management Opposes Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
5. EBRI Policy Forum: Large Employers Continue to Offer Health Benefits
6. NHS Choices Releases New Health A-Z Index
7. McGraw-Hill Higher Education Publishes Text on Innovative Electronic Health Records System
8. Blue Cross and Blue Shield of Illinois Launches Integrated Medical-Dental Health Program
9. MBF Healthcare Acquisition Corp. Announces Signing of Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc.
10. DRAXIS Health Reports Fourth Quarter and Year End Results
11. Gentiva(R) Health Services and CIGNA HealthCare Extend National Homecare Contract Through January 31, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5Ascension Orthopedics Hires Key Senior Executives 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 1FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 2FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 3FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 4VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE 4799 1VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE 4799 2VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE 4799 3Americans Spend Billions on Alternative Medicine 53255 1Americans Spend Billions on Alternative Medicine 53255 2Americans Spend Billions on Alternative Medicine 53255 3
Other Medicine Technology:IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 2IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 3IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 4IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 5Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 2Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 3Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 4Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 5